Melbourne, Mar 19, 2008 (ABN Newswire) - On 28 February 2008, Solagran Limited (ASX: SLA)(PNK: SOGRF) announced to the ASX that Russian regulatory authorities were expected to release its new prescription pharmaceutical Ropren for sale in the Russian market within 1 to 1.5 months. The Directors of Solagran are pleased to announce that this final administrative formality was completed sooner than expected and the official release to market has now been received.
